IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.05

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.13 (-0.09%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.16 (-0.23%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+0.01 (+0.01%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

+0.22 (+0.24%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.03 (-0.13%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.31 (-0.96%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.72 (+0.73%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

-0.13 (-0.41%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.20 (+0.33%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-2.43%)

USD 6.89M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.59% 86% B+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.59% 86% B+ 80% B-
Trailing 12 Months  
Capital Gain 3.88% 67% D+ 46% F
Dividend Return 1.38% 88% B+ 23% F
Total Return 5.26% 71% C- 38% F
Trailing 5 Years  
Capital Gain 29.27% 67% D+ 64% D
Dividend Return 8.73% 95% A 27% F
Total Return 38.00% 76% C+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.17% 48% F 48% F
Dividend Return 5.56% 57% F 45% F
Total Return 1.39% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.35% 71% C- 66% D+
Risk Adjusted Return 36.23% 67% D+ 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike